Medtronic plc(MDT)NASDAQ
Company Profile & Information
Company Profile
Business overview, scale, and footprint
Business Overview
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. It operates through three segments: The Cardiovascular Portfolio, Neuroscience Portfolio, and Medical Surgical Portfolio. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves, left atrial appendage exclusion systems, extracorporeal membrane oxygenation (ECMO) systems and percutaneous coronary intervention products, percutaneous angioplasty balloons, and endovenous products.
The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. This segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists, and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat diseases and conditions, and patient monitoring and airway management products, as well as insulin pumps and consumables, continuous glucose monitoring systems, and sensors. Medtronic plc was founded in 1949 and is headquartered in Galway, Ireland.
Insider Transactions
Open-market activity and option exercises
Insider Activity Summary
Insider trading activity for Medtronic plc (MDT) over the last 3 months consists of 89 total transactions. Among these, company executives and board members conducted 89 buys (totaling 1,076,630 shares) and 0 sells (totaling 0 shares). This activity resulted in a net change of 1,076,630 shares, reflecting net buying interest with an estimated net acquisitions value of $24.97M.
89 insider transactions found. Showing 10 of 89 transactions.
| Insider Name | Relation to Company | Shares Changed | Price | Transaction Date |
|---|---|---|---|---|
| THOMPSON KWELI | Officer | 6,923 | $N/A | Aug 3, 2026 |
| MARTHA GEOFFREY S | Chief Executive Officer | 41,533 | $N/A | Aug 3, 2026 |
| QUINN MICHELLE | General Counsel | 6,346 | $N/A | Aug 3, 2026 |
| MARINARO MICHAEL | Officer | 57,107 | $N/A | Aug 3, 2026 |
| WALTER MATTHEW R. | Officer | 5,769 | $N/A | Aug 3, 2026 |
| PIETON THIERRY JEAN LOUIS | Chief Financial Officer | 11,537 | $N/A | Aug 3, 2026 |
| BLOMQUIST DENISE L | Officer | 2,337 | $N/A | Aug 3, 2026 |
| KIIL HARRY SKIP | Officer | 9,230 | $N/A | Aug 3, 2026 |
| WALTER MATTHEW R. | Officer | 3,102 | $0.26 | Jul 8, 2026 |
| KIIL HARRY SKIP | Officer | 4,189 | $0.34 | Jun 8, 2026 |
Explore More Analysis for MDT
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.